Treating asthma with gene-silencing nanocapsules
Steroid-based inhalers deliver life-saving medication for millions of asthma sufferers, providing relief and the ability to simply breathe. Unfortunately, inhalers do not work for all patients, and with rates on the rise for a disease that leads to hundreds of thousands of deaths worldwide each year, new asthma treatments and strategies are needed.
A team of UConn researchers including Assistant Professor of Chemistry in the College of Liberal Arts and Sciences Jessica Rouge and Associate Professor of Pathobiology in the College of Agriculture, Health, and Natural Resources Steven Szczepanek are collaborating to develop novel asthma therapeutics using gene-silencing nanocapsules in a bid to help patients who aren't benefiting from existing treatments. Their research was published in ACS Nano.
Rouge said, when treating asthma, many people think of small molecule anti-inflammatory medications as the way to go, but there are plenty of patients who have asthma who do not respond to corticosteroids. There's an unmet need for creating different therapeutics that can suppress asthma for this group of people.
Rouge's research group, including co-authors Ph.D. student Shraddha Sawant and Alyssa Hartmann 20 Ph.D., designs nanomaterials and targeted therapeutics that deliver gene silencing messages to cells. This paper details a nucleic acid nanocapsule (NAN) designed to selectively deliver an enzyme, called a DNAzyme, to silence a component of the immune response, called GATA-3, that leads to the over-expression of immune components that play a significant role in allergic asthma attacks.
Szczepanek explains there are different types of asthma, and this technology is designed to treat allergic asthma specifically, which constitutes about 50% of cases in adults and 90% in children. GATA-3-based treatments are already showing promise in clinical trials, and Rouge says that by pairing the sequence with nanotechnology, they hope to provide more efficient means of delivery and treatment straight to the source of inflammation.
Rouge said, when using nanomaterials, we try to administer the therapy in a way that could allow us to use fewer materials to get a bigger effect.
Their system is based on surfactants that assemble into micelles, similar to tiny bubbles, and occurs in a stepwise process, resulting in each being around 60 nanometers in size.
Rouge said, first, we synthesize something called a surfactant, it's much like soap and essentially forms a nanoscale bubble. Then we modify the surface chemistry of this bubble so it can conjugate or connect to DNA. The next step, and what's unique to our lab, is we use enzymes to build the next piece to attach the DNA sequence that essentially cleaves mRNA encoding GATA-3.
The nanocapsules were then characterized and checked if they could cleave the nucleic acid target cell lines in vitro and the results were promising.
Rouge said, we showed these gene-silencing sequences were effectively delivered using our formulation and we saw that they knocked down the gene target of interest. That was an exciting first step.
Rouge brought the data to Szczepanek to see if his research group, including co-authors and graduate students Tyler Gavitt '21 Ph.D. and Arlind Mara '21 Ph.D., who study respiratory pathogens and disease pathology, would be interested in collaborating on the next steps of research to see how technology performed in vivo and if it could be of clinical relevance.
Having studied asthma as part of his post-doctoral research, and with his lab equipped for taking the next steps, Szczepanek said, the collaboration was a natural fit. I thought this gene silencing technology was a fantastic application for asthma therapeutic.
The researchers tested the GATA-3 DNAzyme-NAN efficacy in an allergic asthma mouse model sensitive to house dust mites. The results showed the lungs of mice treated with the NANs had less inflammatory damage compared to the untreated control group. The treatment also reduced the presence of inflammatory immune cells, called eosinophils, which contribute to airway obstruction (see sidebar).
Szczepanek said, not only did we see a substantial reduction of asthma phenotypes in our mouse model, but we tested the GATA-3 DNAzyme-NANs in human white blood cells and saw both uptakes of the nanoparticles and knock-down of expression of the gene of interest. This combination of data makes me really hopeful about the translational potential of the nanoparticles for human health.
Rouge points out another important detail: Generally speaking, when putting nanoparticles in our lungs, you might think they could cause inflammation. However, we were really excited that at doses we used, the nanocarrier alone didn't cause inflammation.
Sawant said, I believe our unique nanoconstruct holds great promise in the field of oligonucleotide delivery. I am happy to be a part of this collaborative research as it marks the beginning of the development of the NAN as an effective in vivo nanocarrier.
Rouge says the next step is to hopefully get NIH funding to continue the research, we want to figure out, Where do these nanocapsules go? We need to do a biodistribution study and other logical next steps, like pharmacokinetics and determining how long these therapeutics last in an organism.
The researchers were recently awarded a patent for the nanocapsule formulation, and they hope to commercialize it. Szczepanek explains the team envisions that, eventually, the technology could be delivered to the patient via an inhaler, like current asthma medications are and, depending on exactly how it is formulated, that it could target active inflammation or act as a prophylactic measure. Rouge adds that this technology has the potential to be customizable.
Rouge said, the major theme is that different people respond differently to diseases in general, so there is the potential for personalized medicine. We are looking toward a paradigm shift because if you know the genetics of somebody in terms of the intensity or overexpression of a particular gene or if it is upregulated, we could treat it or at least depress it.
Szczepanek explains that allergic asthma results when the immune system becomes sensitized to something ubiquitous and generally harmless in the environment, like house dust mites.
Szczepanek said, sensitization pushes the memory component of our T-cells into what's called a Th2 phenotype. T-cells are part of our adaptive immune system that remembers previous exposure to a stimulus that we had to mount an immune response against. Usually, these are bacteria and viruses, which is a good thing, since we want to remember pathogens like the flu, for example. But it's not good when you're mounting an immune response against dust that's in the air all the time, because it can lead to some pretty severe side effects. Outcomes and severity vary from person to person.
Szczepanek said, we see inflammation of the airways resulting from more immune cells making their way into the air spaces, and that's going to make the airways smaller. Those cells activate goblet cells in the airways, which are cells that produce mucus and when you hyper-activate these goblet cells, you get tons of mucus going into the airways that are already inflamed and therefore constrictive. That creates more and more of a problem and reduces the ability of an asthmatic to breathe during an asthma attack. And then lastly, you also get bronchoconstriction, which happens when the layer of smooth muscle surrounding the bronchioles of the lungs constricts. It's a significant public health problem because a very large portion of the population is susceptible to developing asthma.
Journal Information: Tyler D. Gavitt et al, A GATA3 Targeting Nucleic Acid Nanocapsule for In Vivo Gene Regulation in Asthma, ACS Nano (2021). DOI: 10.1021/acsnano.0c07781